Clinical Trials on Influenza Like Illness

Total 9941 results

Pharmenterprises Biotech LLC

Completed

Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administrations in Healthy Volunteers

Influenza A

Russian Federation
GlaxoSmithKline

Terminated

Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

Influenza | Influenza Vaccines

Spain
GlaxoSmithKline

Completed

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza | Influenza Vaccines

Germany
The University of Hong Kong

Unknown

Flufenamic Acid for Hospitalised Influenza Infection

Influenza A

Hong Kong
GlaxoSmithKline

Completed

A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk

Influenza Vaccines

Canada
PharmaJet, Inc.

Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Influenza Prophylaxis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

Prophylaxis: Influenza

United States
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
The University of Texas Health Science Center,...
Gilstrap, Larry C, M.D.

Completed

Opting In vs Opting Out

Influenza Vaccination

United States
Butantan Institute

Completed

Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute (FLU-05-IB)

Influenza Vaccines

Brazil
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
University of Pennsylvania
Yale University; Stanford University; Harvard University

Completed

The Effect of Time-Slot Scheduling on Flu Vaccination Rates

Seasonal Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
Novartis
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.

Human Influenza

Brazil
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Butantan Institute
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients

Human Influenza

Brazil
University of Alberta

Completed

Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients

Influenza Vaccine

Canada
Centers for Disease Control and Prevention
Universidad del Valle, Guatemala; Hospital Nacional San Juan de Dios de Santa... and other collaborators

Terminated

Panama and El Salvador Children's Oseltamivir Study (PECOS)

Influenza | Human Influenza

Panama, El Salvador
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Influenza (Pandemic)

United States
Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Novavax

Completed

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

Seasonal Influenza

United States
Hualan Biological Engineering, Inc.

Completed

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Human Influenza

China
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza (PIPET A)

Pandemic Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects

Influenza Disease

Italy
Assistance Publique - Hôpitaux de Paris
GlaxoSmithKline; Hoffmann-La Roche

Terminated

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir (BIVIR)

Gastric Influenza

France
Meso Scale Diagnostics, LLC.
Centers for Disease Control and Prevention

Terminated

Clinical Validation of the Point-of-Care MSD Influenza Test

Influenza Human

United States
Novartis Vaccines

Completed

Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers

Seasonal Influenza

Vietnam
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
Chinese Academy of Sciences
Jiangsu Province Centers for Disease Control and Prevention; Hualan Biological...

Unknown

Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Human Influenza

China
PowderMed

Completed

Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu

Influenza (Pandemic)

United Kingdom
University Hospital Birmingham NHS Foundation Trust

Completed

Outpatient Based Physical Rehabilitation for Survivors of Prolonged Critical Illness

Rehabilitation After Critical Illness
Rambam Health Care Campus

Unknown

From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management

Patients Diagnosed With Severe Mental Illness

Israel
Hvivo
Pfizer

Recruiting

Dose, Safety, and Pathogenicity of a New Influenza B Strain

Influenza B

United Kingdom
National Institute of Allergy and Infectious Diseases...

Recruiting

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

Influenza Infection

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza (OPTIFLU)

Severe Influenza

France
Changchun BCHT Biotechnology Co.
He Bei province Center for Disease control and prevention

Recruiting

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

Influenza Prevention

China
Sinovac Biotech Co., Ltd
Pontificia Universidad Catolica de Chile; Sinovac Biotech Co., Ltd

Completed

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Seasonal Influenza

Philippines, Chile
ModernaTX, Inc.

Active, not recruiting

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303)

Seasonal Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Imperial College London
Public Health England

Completed

Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children (FluSHED-2)

Influenza Vaccines

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults

Influenza | Seasonal Influenza

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Influenza | Influenza Immunisation

United States

3

Subscribe